Exchange: NASDAQ·Updated 07:30 PM EST
RNAC logo

RNAC Selecta Biosciences Inc

$6.10
$0.25
(4.24%)
Today
Closed $6.14
$0.04
(0.65%)
After Hours
Reported EarningsNov 5
Mkt Cap$187.29M
Vol279,909.00

About RNAC

Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in mRNA cell therapies for the treatment of autoimmune diseases. It operates in research and development of cell therapy product candidates. The company was founded on December 10, 2007 is headquartered in Frederick, MD.
69

Bullish Sentiment

How do you feel about RNAC?

FetchDog
$RNAC If their clinical trials continue meeting objectives (I think very likely), their peak annual sales from Descartes-08 (according to Gemini AI): Peak annual US revenue estimates for Descartes-08 (Gemini AI) AChR+ gMG : $450 million to $650 million Myositis : $350 million to $450 million JDM : $150 million to $250 million For Descartes-08 revenue, I'm guessing their market cap multiplier realtive to sales will be a modest 4x due to high costs of goods and sales/marketing. I could be way off on this. The biggest upside potential may come from their "In Vivo CAR-T Platform" (WestGene LNP platform with Cartesian’s mRNA payload). Initial phase-1 ata for this platform in 2027-H1.
2
FetchDog
$RNAC There are a number of biotech stocks I want to build positions in (for a long term hold) during november and early december, and RNAC is one of them. Last Friday's large green candle means there is a good possibility that RNAC's downward slide is over. I got my starter position in RNAC on Friday and today, and I hope to add a bit more or RNAC if it retraces a bit. I was forced to wait to buy RNAC due to my limited / conservative cash position (no margin in this volatile market). I keep part in cash for day trading, and profits from that go to buying long term holds like RNAC. My cash position has improved substantially in recent days from day trading, especially in volatile tech stocks like $MU. The current market is good for day traders.
1
InjureReserve
$RNAC As of September 30, 2026, Barclays reported: * Previous: 1,760,326 RNAC shares * Latest: 7,233 shares * Change: −1,753,093 shares * Reduction: 99.59% * Ownership fell from 5.99% → 0.02%. The filing was accepted November 6, 2026, so this is the newest Barclays disclosure. Barclays essentially exited the position between June 30 and September 30.

Advertisement|Remove ads.